71.57

0.67% 0.44

Astrazeneca PLC (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$71.13

Aprire:

$71.35

Volume 24 ore:

855.13K

Relative Volume:

0.18

Capitalizzazione di mercato:

$221.96B

Reddito:

$54.98B

Utile/perdita netta:

$7.77B

Rapporto P/E:

28.74

EPS:

2.49

Flusso di cassa netto:

$9.14B

1 W Prestazione:

+2.84%

1M Prestazione:

-3.78%

6M Prestazione:

+9.55%

1 anno Prestazione:

-9.63%

Intervallo 1D:

$71.20

$71.76

Intervallo di 1 settimana:

$69.15

$72.46

Portata 52W:

$61.24

$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Nome

Astrazeneca PLC

Settore

Healthcare (1169)

Industria

Drug Manufacturers - Major (1)

Telefono

44 20 3749 5000

Indirizzo

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge

Dipendente

61,100

Cinguettio

@AstraZeneca

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

AZN's Discussions on Twitter

Confronta AZN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AZN Astrazeneca PLC	71.57	215.88B	54.98B	7.77B	9.14B	2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-15	Iniziato	Exane BNP Paribas	Outperform
2025-02-13	Aggiornamento	UBS	Neutral → Buy
2025-02-12	Iniziato	Morgan Stanley	Overweight
2024-11-20	Aggiornamento	UBS	Sell → Neutral
2024-11-06	Aggiornamento	Deutsche Bank	Sell → Hold
2024-09-13	Downgrade	Deutsche Bank	Hold → Sell
2024-05-30	Iniziato	Goldman	Buy
2024-04-16	Aggiornamento	Deutsche Bank	Sell → Hold
2024-02-08	Downgrade	Deutsche Bank	Hold → Sell
2024-01-23	Iniziato	Morgan Stanley	Overweight
2024-01-16	Ripresa	UBS	Sell
2024-01-03	Downgrade	Jefferies	Buy → Hold
2023-12-18	Iniziato	HSBC Securities	Buy
2023-09-25	Aggiornamento	Jefferies	Hold → Buy
2023-07-14	Iniziato	HSBC Securities	Buy
2023-07-12	Aggiornamento	UBS	Neutral → Buy
2023-07-05	Downgrade	Deutsche Bank	Buy → Hold
2023-04-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-01-05	Iniziato	BMO Capital Markets	Outperform
2022-09-15	Downgrade	Credit Suisse	Outperform → Neutral
2022-09-07	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-08-29	Aggiornamento	Argus	Hold → Buy
2022-06-14	Downgrade	UBS	Buy → Neutral
2022-02-11	Aggiornamento	DZ Bank	Sell → Hold
2021-12-07	Downgrade	Jefferies	Buy → Hold
2021-08-12	Ripresa	JP Morgan	Overweight
2021-04-12	Downgrade	Argus	Buy → Hold
2021-03-16	Aggiornamento	Jefferies	Hold → Buy
2021-02-25	Aggiornamento	UBS	Neutral → Buy
2021-01-15	Iniziato	Deutsche Bank	Buy
2020-12-07	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-11-30	Aggiornamento	UBS	Sell → Neutral
2020-11-11	Aggiornamento	HSBC Securities	Reduce → Hold
2020-09-29	Iniziato	Berenberg	Buy
2019-11-22	Iniziato	SVB Leerink	Outperform
2019-10-25	Aggiornamento	Liberum	Hold → Buy
2019-04-02	Downgrade	UBS	Neutral → Sell
2019-02-05	Iniziato	Exane BNP Paribas	Outperform
2019-01-25	Aggiornamento	Shore Capital	Hold → Buy
2018-12-11	Ripresa	Jefferies	Hold
2018-10-09	Iniziato	Guggenheim	Buy
2018-08-16	Downgrade	Jefferies	Buy → Hold
2018-03-19	Aggiornamento	Jefferies	Hold → Buy
2018-02-06	Reiterato	Leerink Partners	Mkt Perform
2018-02-05	Reiterato	Bernstein	Outperform
2018-01-18	Reiterato	Leerink Partners	Mkt Perform
2017-12-29	Aggiornamento	JP Morgan	Neutral → Overweight
2017-10-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2017-09-25	Aggiornamento	Exane BNP Paribas	Neutral → Outperform
2017-09-22	Aggiornamento	Bernstein	Mkt Perform → Outperform

Mostra tutto

Astrazeneca PLC Borsa (AZN) Ultime notizie

10:17 AM

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com

10:17 AM

09:28 AM

AstraZeneca's baxdrostat meets key goals in late-stage trial for hypertension - Seeking Alpha

09:28 AM

09:05 AM

AstraZeneca's Drug Shows Promise for Resistant HypertensionAstraZeneca (NASDAQ:AZN) - Benzinga

09:05 AM

06:30 AM

AstraZeneca gains on successful trial for blood pressure drug, 14 Jul 2025 11:30 - Shares Magazine

06:30 AM

05:29 AM

AstraZeneca drug lowers high blood pressure in late-stage study; shares rise - MarketScreener

05:29 AM

05:05 AM

Astra says potential blockbuster reduced high blood pressure - Moneycontrol

05:05 AM

04:29 AM

AstraZeneca says potential blockbuster reduced high blood pressure - The Edge Malaysia

04:29 AM

04:27 AM

AstraZeneca: conclusive results against hypertension - MarketScreener

04:27 AM

04:10 AM

AstraZeneca shares gain after drug shows success in late-stage hypertension trial - Investing.com UK

04:10 AM

03:26 AM

AstraZeneca drug lowers high BP in late-stage study; shares rise - MarketScreener

03:26 AM

02:40 AM

AstraZeneca drug meets all goals in high blood pressure study - MarketScreener

02:40 AM

02:27 AM

AstraZeneca says baxdrostat met primary and secondary endpoints in Phase III trial - MarketScreener

02:27 AM

02:26 AM

AstraZeneca's Baxdrostat Meets Phase III Endpoints In Hypertension Trial - DirectorsTalk Interviews

02:26 AM

12:00 PM

An AstraZeneca Exit Wouldn’t Doom London - Bloomberg.com

12:00 PM

Jul 12, 2025

AstraZeneca’s New Study on CKD Treatment: Potential Market Impacts - The Globe and Mail

Jul 12, 2025

Jul 11, 2025

AstraZeneca’s Tozorakimab Study: A New Frontier in Drug Delivery - The Globe and Mail

Jul 11, 2025

AstraZeneca’s Innovative Cancer Study: AZD7789’s Potential Impact - The Globe and Mail

Jul 11, 2025

AstraZeneca’s SERENA-1 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks

Jul 11, 2025

AstraZeneca Completes Key Study on Asthma and COPD Diagnostics - TipRanks

Jul 11, 2025

AstraZeneca Completes Key Study on Hyperkalemia Management in Heart Failure - TipRanks

Jul 11, 2025

AstraZeneca’s PRIMULA Preg Study: Assessing Anifrolumab’s Impact on Pregnancy Outcomes - TipRanks

Jul 11, 2025

AstraZeneca’s Osimertinib Study Update: Potential Market Impact - The Globe and Mail

Jul 11, 2025

AstraZeneca’s TROPION-PanTumor03: A Promising Phase II Study in Oncology - TipRanks

Jul 11, 2025

AstraZeneca’s TRIXEO Study: Real-World Insights into COPD Treatment - TipRanks

Jul 11, 2025

AstraZeneca’s CKD Registry Study: A New Frontier in Chronic Kidney Disease Research - TipRanks

Jul 11, 2025

AstraZeneca’s Latest Study on AZD4248: A Potential Game-Changer in Diabetes and Kidney Disease Treatment - TipRanks

Jul 11, 2025

AstraZeneca’s Latest Study on AZD2389: What Investors Need to Know - TipRanks

Jul 11, 2025

AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead - Proactive Investors

Jul 11, 2025

Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong - GlobeNewswire Inc.

Jul 11, 2025

AstraZeneca’s SERENA-1 Study: A Promising Development in Breast Cancer Treatment - TipRanks

Jul 11, 2025

Jul 10, 2025

AstraZeneca’s UmbREALung Study: Real-World Insights into NSCLC Treatment - TipRanks

Jul 10, 2025

AstraZeneca’s Real-world Study on Anifrolumab: Implications for Investors - TipRanks

Jul 10, 2025

Eli Lilly and AstraZeneca’s Promising Study on KRAS G12C-Mutant Lung Cancer - TipRanks

Jul 10, 2025

AstraZeneca’s CAR-T Therapy Study for Liver Cancer: Key Insights for Investors - TipRanks

Jul 10, 2025

AstraZeneca’s Innovative PET Study on Crohn’s Disease: Market Implications and Progress - TipRanks

Jul 10, 2025

AstraZeneca’s Observational Study on Tezepelumab: A New Hope for Severe Asthma Patients - TipRanks

Jul 10, 2025

AstraZeneca’s PROGRESS-CKD Study: A Step Forward in Understanding Hypertension and Kidney Disease - TipRanks

Jul 10, 2025

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - Yahoo

Jul 10, 2025

AstraZeneca’s ASCENT Study: Real-World Insights on Tezepelumab for Severe Asthma - TipRanks

Jul 10, 2025

Jul 09, 2025

AstraZeneca’s NASH Study Completes: Market Implications of AZD4831 - TipRanks

Jul 09, 2025

AstraZeneca’s Latest Study on Inhaler Propellants: Key Insights for Investors - TipRanks

Jul 09, 2025

AstraZeneca’s Real-World Study on Dapagliflozin: A Strategic Move in Heart Failure Treatment - TipRanks

Jul 09, 2025

AstraZeneca’s New CKD Study: A Potential Game-Changer? - TipRanks

Jul 09, 2025

AstraZeneca’s SZC Study Completion: Impact on Hyperkalemia Management - TipRanks

Jul 09, 2025

Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Yahoo Finance

Jul 09, 2025

AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank - Proactive Investors

Jul 09, 2025